Onkológia 6/2025
Drug profile – loncastuximab tesirine
Diffuse large B-cell lymphoma (DLBCL) is the most common type of malignant lymphoma. Patients often require urgent initiation of therapy, with more than half achieving cure. Nevertheless, a significant proportion relapse or become refractory to standard immunochemotherapy, and their prognosis remains poor. Loncastuximab tesirine consists of a monoclonal anti-CD19 antibody linked to a cytotoxic pyrrolobenzodiazepine payload. The drug has been approved as monotherapy for adult patients with relapsed or refractory (R/R) DLBCL after at least two prior lines of therapy. The LOTIS-1 and LOTIS-2 clinical trials demonstrated meaningful efficacy, with overall response rates of approximately 40 – 50% and durable remissions even in high-risk subgroups. The safety profile is generally manageable. Specific adverse events include phototoxicity, edema, and elevations in liver enzymes. Hematologic toxicities such as neutropenia and anaemia are also common. In clinical studies, treatment was well tolerated even in elderly patients over 75 years of age. Loncastuximab tesirine represents an effective and promising treatment option for patients with R/R DLBCL who have exhausted available standard therapies.
Keywords: loncastuximab tesirine, lymphoma, therapy
